All data are based on the daily closing price as of June 27, 2025
p
Pharmicell
005690.KO
9.86 USD
-0.42
-4.09%
Overview
Last close
9.86 usd
Market cap
591.49M usd
52 week high
10.28 usd
52 week low
3.14 usd
Target price
12.83 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
33.5544
Price/Book Value
8.574
Enterprise Value
581.00M usd
EV/Revenue
9.7973
EV/EBITDA
39.9487
Key financials
Revenue TTM
17.55M usd
Gross Profit TTM
3.99M usd
EBITDA TTM
-4.53M usd
Earnings per Share
N/A usd
Dividend
0.01 usd
Total assets
71.95M usd
Net debt
N/A usd
About
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; Hearticellgram_AMI, a cardiac disease drug; Cellgram_CKD for the treatment of chronic kidney disease; and Cellgram_AKI for the treatment of acute kidney disease. It develops and produces intermediates of raw material medicines, such as nucleosides and mPEGs; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company provides Half-Serum DMEM, as well as clinical development and commercialization services for new drugs. Further, it operates Twelve, a stem cell bank; and develops and sells stem cell culture media cosmetics. The company was formerly known as FcB2welve Co., Ltd and changed its name to Pharmicell Co., Ltd. in September 2011. Pharmicell Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea.